TY - JOUR
T1 - Conversion of L-dopa to extended release L-dopa (Rytary ® ) in patients with fluctuating Parkinson's disease
T2 - Predictors of dose
AU - Ondo, William
AU - Coss, Pablo
AU - Christie, Melissa
AU - Pascual, Belen
N1 - Publisher Copyright:
© 2019 IOS Press and the authors. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Background: A new extended release levodopa capsule (C/L ERC), Rytary® , has demonstrated improved "on" time in fluctuating Parkinson's disease patients, compared to optimally dosed immediate release levodopa. The milligram dosing, however, differs markedly and no empiric ratio or formula for dose conversion currently exists. Objective: To determine the most effective conversion strategy from C/L to C/L ERC. Methods: We reviewed fluctuating PD patients with problematic "off" time who were converted to C/L ERC using a semistructured dose titration schedule, and collected data regarding basic efficacy, tolerability, and dosing, in order to determine an empirically based dose conversion formula. We collected demographics, PD historic data, and other medication use. Results: Eighty fluctuating PD patients were given C/L ERC samples, 68 took at least one dose [46 male (67.6%), age 66.6±10.3 y], and 62 had adequate data for dose convergence calculations. At a mean follow-up of 119±101 days, [Range: 24-355 days], 43/68 (63.3%) remained on C/L ERC. CGI-I of "much improved" or "very much improved" was reported by 27/62 (43.5%) and dyskinesia scores from the Movement Disorder Society Unified Parkinson's Disease Rating Scale item 4.1, (0-4 range)) tended to improve from 0.9±1.1 to 0.5±0.6, P = 0.08. The mean individual daily ratio was 2.0±0.6 : 1, [range 1.0-3.5]. A lower number of baseline daily L-dopa doses predicted a higher conversion ratio, but pre-conversion dyskinesia did not. Conclusions: This retrospective study found that C/L ERC was generally well tolerated and preferred by many patients. The mean total daily conversion ratio is 2 : 1.
AB - Background: A new extended release levodopa capsule (C/L ERC), Rytary® , has demonstrated improved "on" time in fluctuating Parkinson's disease patients, compared to optimally dosed immediate release levodopa. The milligram dosing, however, differs markedly and no empiric ratio or formula for dose conversion currently exists. Objective: To determine the most effective conversion strategy from C/L to C/L ERC. Methods: We reviewed fluctuating PD patients with problematic "off" time who were converted to C/L ERC using a semistructured dose titration schedule, and collected data regarding basic efficacy, tolerability, and dosing, in order to determine an empirically based dose conversion formula. We collected demographics, PD historic data, and other medication use. Results: Eighty fluctuating PD patients were given C/L ERC samples, 68 took at least one dose [46 male (67.6%), age 66.6±10.3 y], and 62 had adequate data for dose convergence calculations. At a mean follow-up of 119±101 days, [Range: 24-355 days], 43/68 (63.3%) remained on C/L ERC. CGI-I of "much improved" or "very much improved" was reported by 27/62 (43.5%) and dyskinesia scores from the Movement Disorder Society Unified Parkinson's Disease Rating Scale item 4.1, (0-4 range)) tended to improve from 0.9±1.1 to 0.5±0.6, P = 0.08. The mean individual daily ratio was 2.0±0.6 : 1, [range 1.0-3.5]. A lower number of baseline daily L-dopa doses predicted a higher conversion ratio, but pre-conversion dyskinesia did not. Conclusions: This retrospective study found that C/L ERC was generally well tolerated and preferred by many patients. The mean total daily conversion ratio is 2 : 1.
KW - Parkinson's disease
KW - levodopa
KW - rytary
UR - http://www.scopus.com/inward/record.url?scp=85061205754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061205754&partnerID=8YFLogxK
U2 - 10.3233/JPD-181427
DO - 10.3233/JPD-181427
M3 - Article
C2 - 30400106
AN - SCOPUS:85061205754
SN - 1877-7171
VL - 9
SP - 153
EP - 156
JO - Journal of Parkinson's Disease
JF - Journal of Parkinson's Disease
IS - 1
ER -